Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Marc Hilmi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4762-6740; OpenAlex author ID A5046106054. Sources: OpenAlex.

Their work

Papers
17 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
80
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 6 papers

Papers 17

  1. Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. First author DOI 10.1016/j.dld.2026.10.006↗
  2. Genomic evolution of pancreatic cancer at single-cell resolution. Co-author DOI 10.1038/s41588-025-02468-9↗
  3. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  4. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  5. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study First author DOI 10.64898/2026.06.18.26355998↗
  6. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  7. Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity. Co-author DOI 10.1002/jcsm.13595↗
  8. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Co-author DOI 10.1002/path.6398↗
  9. [NALIRIFOX in first-line therapy for metastatic pancreatic adenocarcinoma]. First author DOI 10.1016/j.bulcan.2024.06.007↗
  10. Codon-specific KRAS mutations predict survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2023.100030↗
  11. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. Co-author DOI 10.1016/s2468-1253(23)00207-8↗
  12. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenoc… Co-author DOI 10.1002/path.6011↗
  13. Microbiome and pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.clinre.2020.101589↗
  14. Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2021.01.042↗
  15. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation]. Co-author DOI 10.1016/j.bulcan.2020.06.009↗
  16. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Co-author DOI 10.1177/1758835920937949↗
  17. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? Co-author DOI 10.3748/wjg.v24.i20.2137↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cindy Neuzillet · 10 shared papers, 2018–2026 · strength 1.87
  2. Pascal R. Hammel · 5 shared papers, 2020–2026 · strength 0.88
  3. Jerome F. Cros · 5 shared papers, 2021–2026 · strength 0.87
  4. Rémy Nicolle · 5 shared papers, 2021–2025 · strength 0.81
  5. Déwi Vernerey · 3 shared papers, 2025–2026 · strength 0.70
  6. Wungki Park · 3 shared papers, 2026 · strength 0.60
  7. Eileen Mary O'Reilly · 3 shared papers, 2026 · strength 0.60
  8. Christine A. Iacobuzio–Donahue · 3 shared papers, 2026 · strength 0.60
  9. Benoı̂t Rousseau · 3 shared papers, 2026 · strength 0.59
  10. Jean‐Baptiste Bachet · 3 shared papers, 2021–2026 · strength 0.59
  11. Siriane Anglaret · 1 shared paper, 2024 · strength 0.46
  12. Matthieu Delaye · 2 shared papers, 2023–2026 · strength 0.44
  13. Victoire Cardot‐Ruffino · 2 shared papers, 2023–2026 · strength 0.44
  14. Caitlin A. McIntyre · 2 shared papers, 2026 · strength 0.42
  15. Akimasa Hayashi · 2 shared papers, 2026 · strength 0.42
  16. Haochen Zhang · 2 shared papers, 2026 · strength 0.42
  17. Alice Chia-Chi Wei · 2 shared papers, 2026 · strength 0.42
  18. Benjamin D. Greenbaum · 2 shared papers, 2026 · strength 0.37
  19. Olca Baştürk · 2 shared papers, 2026 · strength 0.37
  20. Marinela Capanu · 2 shared papers, 2026 · strength 0.37
  21. Dana Pe'er · 2 shared papers, 2026 · strength 0.37
  22. Vinod P. Balachandran · 2 shared papers, 2026 · strength 0.37
  23. Kevin C. Soares · 2 shared papers, 2026 · strength 0.37
  24. Nuray Tezcan · 2 shared papers, 2026 · strength 0.37
  25. Fiyinfolu O. Balogun · 2 shared papers, 2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.